Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, ItalyArticle Published on 2020-08-202022-10-31 Journal: Cancers [Category] COVID-19, [키워드] analysed appear Cancer cancer care cancer centre cancer patient Cancer patients Care Chemotherapy China Clinical characteristics Combination continuum correlation COVID-19 Fatality rate General population hospitalisation Immunotherapy In-hospital incidence Infection intravenous Italy lombardy material median median age metastatic disease outcome pandemic Patient Prognosis Registered reported required resulting retrospective data risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-positive patient SARS-CoV-2-positive patients Solid solid tumour targeted therapy Tertiary therapy treated Treatment treatment safety [DOI] 10.3390/cancers12092352 PMC 바로가기 [Article Type] Article
Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19Molecular Biosciences Published on 2020-08-112022-10-31 Journal: Frontiers in Molecular Biosciences [Category] COVID-19, [키워드] ACE2 ACE2 receptor Activation acute lung injury Against airway epithelial cells antibody appear approach can be used caused cell receptor cellular cleavability complement contagious coronavirus coronavirus disease correlated COVID-19 cytokine Cytokine storm disease disease severity docking drug candidate early phase Effect enzyme excessive inflammatory response expressed expression Factor followed by help highlight highly pathogenic host cells Host immune response host tropism humans IL-6 immune dysregulation immunomodulator immunomodulators inflammatory mediator Innate immunity Interaction involved Lung inflammation mannose-binding lectin mechanism MERS-CoV molecular novel Occurrence pathogenic Proinflammatory cytokine Protein proteolytic recombinant Research respiratory epithelial cell Respiratory tract infections S protein SARS-CoV SARS-CoV-2 SARS-COV-2 infection secreted spike Strategy targeted therapy Therapeutic approach TMPRSS2 understanding Vaccine viral infection Viral pneumonia virulence virus with COVID-19 [DOI] 10.3389/fmolb.2020.00196 PMC 바로가기 [Article Type] Molecular Biosciences
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction StrategiesReview Article Published on 2020-08-102022-10-29 Journal: Pulmonary Medicine [Category] COVID-19, MERS, SARS, [키워드] absence acute respiratory distress advanced age Autopsy clinically complicate connective tissue COVID-19 COVID-19 infection Diseases disorders effective evaluate Evidence Factor fibrosis ICU Illness severity indicated Infection inflammatory phase initial lung lung dysfunction Lung fibrosis Lung injury measure mechanical ventilation medications MERS occur Pathogenesis pathology predictor pulmonary pulmonary fibrosis Radiographic respiratory infections risk risk factor risk reduction SARS-CoV-2 severe lung injury severity smoking Strategy Support syndrome targeted therapy the disease [DOI] 10.1155/2020/6175964 PMC 바로가기 [Article Type] Review Article
ENDOCRINOLOGY IN THE TIME OF COVID-19: Clinical management of neuroendocrine neoplasms (NENs)Clinical Practice Guidance Published on 2020-08-092022-10-31 Journal: European Journal of Endocrinology [Category] COVID-19, MERS, [키워드] Chemotherapy clinical develop diagnosed disease Effect Follow-up functional genetic disorder growth Immunotherapy indolent interferon-alpha intestine life-threatening lung management medullary thyroid carcinoma Mild neoplasm neuroendocrine pancreas Pandemics Patient patients presenting receiving risk severity Surveillance Symptom syndrome targeted therapy therapy treated Treatment viral infection [DOI] 10.1530/EJE-20-0424 PMC 바로가기 [Article Type] Clinical Practice Guidance
Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional studyOriginal Article Published on 2020-08-052024-09-04 Journal: The Breast [Category] 대상포진, [키워드] Breast cancer Chemotherapy Dry eye NFBSI-16 OSDI PRO measures questionnaire targeted therapy [DOI] 10.1016/j.breast.2020.07.009 PMC 바로가기 [Article Type] Original Article
COVID 19 therapies and anti-cancer drugs: A systematic review of recent literatureReview article Published on 2020-08-012022-10-05 Journal: Critical Reviews in Oncology/Hematology [Category] SARS, 치료제, [키워드] ACE2angiotensin-converting enzyme 2 AIFAItalian Medicines Agency (Agenzia Italiana del Farmaco) androgen receptor signaling inhibitors angiotensin-converting enzyme 2 antineoplastic drugs ARSIandrogen receptor signaling inhibitors article Cancer cancer patient checkpoint inhibitors Chemotherapy Clinical practice clinical trial Colchicine conducted Corona Virus Disease Course COVID COVID 19 COVID-19 COVID-19 pandemic COVID-19corona virus disease CPIcheckpoint inhibitors CYPcytochrome P450 cytochrome P450 Dipeptidyl peptidase 4 disease disease-modifying antirheumatic drugs DMARDsdisease-modifying antirheumatic drugs DPP4Dipeptidyl peptidase 4 drug drug interaction Future highlight HIV-1human immunodeficiency virus Human immunodeficiency virus IL6Interleukin 6 Immunotherapy Inconclusive Interaction interleukin 6 Italian Medicines Agency (Agenzia Italiana del Farmaco) literature review oncologist positive provide Result ruxolitinib systematic review targeted therapy therapy Tocilizumab Treatment treatments for COVID-19 [DOI] 10.1016/j.critrevonc.2020.102991 [Article Type] Review article
Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 TreatmentReview Article Published on 2020-07-162022-10-31 Journal: Mediators of Inflammation [Category] COVID-19, MERS, SARS, [키워드] Activation Affect autophagy build caused clinical picture COVID-19 damage-associated molecular pattern damaged DAMPs excessive inflammatory response HMGB1 immune response increase in induce Inflammation Innate immunity lung cell NETosis NETs neutrophil Neutrophil extracellular trap new coronavirus SARS-CoV-2 pandemic disease pattern Potential released Respiratory system robust SARS-COV-2 infection sustained target targeted therapy the disease Treatment viruses [DOI] 10.1155/2020/7527953 PMC 바로가기 [Article Type] Review Article
Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing?Editorial Published on 2020-06-102022-10-28 Journal: Pharmacogenomics [Category] COVID-19, SARS, [키워드] Cancer COVID-19 neoplasm SARS-CoV-2 targeted therapy therapy [DOI] 10.2217/pgs-2020-0059 PMC 바로가기 [Article Type] Editorial
Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, ChinaReview Published on 2020-06-062022-10-28 Journal: Annals of Intensive Care [Category] COVID-19, [키워드] assigned China clinical evidence coronavirus disease COVID-19 COVID-19 epidemic COVID-19 patients COVID-2019 Critical care Critically ill Critically ill patient develop Diagnosis draft dynamic epidemiological etiological Expert statement functional GRADE Grade 1 Immunity impairment intensive care management organ organ function organized pandemic Part participant Patient Psychological interventions recommendation recommendations resource Result Support Supportive treatment targeted therapy therapy tissue Treatment was obtained with COVID-19 Wuhan Wuhan, China [DOI] 10.1186/s13613-020-00689-1 PMC 바로가기 [Article Type] Review
Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology toolsArticle Published on 2020-05-302023-06-16 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] MERS, SARS, [키워드] ACE2, Angiotensin I converting enzyme 2 ARDS, acute respiratory distress syndrome BXTM, banxia tianma baizhu tang (TCM herbs) COVID-19 COVID-19, 2019 novel coronavirus disease HSZF, hanshi zufei fang (TCM herbs) LHQW, lian hua qing wen (TCM herbs) network pharmacology PDL, Pudilan (TCM herbs) SARS-COV-2 infection SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SFJD, shufeng jiedu fang (TCM herbs) targeted therapy TCM, traditional Chinese medicine Traditional Chinese herbs [DOI] 10.1016/j.biopha.2020.110316 PMC 바로가기 [Article Type] Article